AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1831686
Drug: Daily supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supervised toothbrushing with three-monthly scale and polish and reinforcement of oral hygiene instruction (Group 3)
Trial: 1831686
Drug: Daily supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supervised toothbrushing with one-monthly input from a dental hygienist (Group 4)
Trial: 1831686
Drug: Daily supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supervised toothbrushing without additional treatment (Control group)
Trial: 1831686
Drug: Daily supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supervised toothbrushing with three-monthly scale and polish (Group 3)
Trial: 7159690
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet containing 25 mg bemetizide and 50 mg triamterene
Trial: 7159690
Drug: Bemetizide alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemetizide alone (25 mg)
Trial: 7159690
Drug: Triamterene alone
RxNorm normalized name: Triamterene
DrugBank: Triamterene (DB00384)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamterene alone (50 mg)
Trial: 31033867
Drug: Sodium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium intake of 2,400 mg per day
Trial: 31033867
Drug: Sodium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium intake of 1,500 mg per day
Trial: 26010521
Drug: 21‐mg transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21‐mg transdermal nicotine patch
Trial: 22015074
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion (30-minute intravenous infusion)
Trial: 18091545
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with meropenem (1 g every 8 hrs) and ciprofloxacin (400 mg every 12 hrs)
Trial: 18091545
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with meropenem alone
Trial: 8203833
Drug: Cefepime (CP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (CP; 2.0 g IV every 12 h)
Trial: 8203833
Drug: Ceftazidime (CZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (CZ; 2.0 g IV every 8 h)
Trial: 31863557
Drug: Metformin (1450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1450 ± 550 mg/day)
Trial: 1396725
Drug: Cefuroxime 750
RxNorm normalized name: cefuroxime 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 750 mg t.i.d. followed by oral cefuroxime axetil 500 mg b.i.d.
Trial: 1396725
Drug: Amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin plus clavulanic acid (1.2 g intravenously t.i.d. followed by 625 mg orally t.i.d.)
Trial: 1396725
Drug: Amoxicillin/CA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/CA
Trial: 3091097
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day methylene blue
Trial: 3091097
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day methylene blue (control)
Trial: 30532527
Drug: Calcitriol 0.5
RxNorm normalized name: CALCITRIOL 0.5MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 0.5 µg/day
Trial: 24277915
Drug: Silirum vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silirum vaccine
Trial: 22176900
Drug: Yinzhihuang oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yinzhihuang oral liquid combined with phototherapy
Trial: 18831071
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (PASCET-PI)
Trial: 17571600
Drug: Milrinone (M
RxNorm normalized name: Product containing milrinone (medicinal product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (M group) administered continuously at a rate of 0.15‐0.30 microg x kg(‐1) min(‐1) after sternotomy until the end of operation.
Trial: 15257113
Drug: Medication NR
RxNorm normalized name: carbinoxamine maleate Oral Solution [Cordron NR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication NR
Trial: 15257113
Drug: Medication RES
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication RES
Trial: 11448916
Drug: Antiangiogenic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiangiogenic therapy with razoxane
Trial: 8064281
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with radiation therapy
Trial: 8064281
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy alone (Control)
Trial: 4951240
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg fentanyl intramuscularly
Trial: 4951240
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg morphine intramuscularly
Trial: 27171508
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg once daily (monotherapy)
Trial: 27171508
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg once daily (add-on to metformin)
Trial: 27171508
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg once daily (add-on to pioglitazone)
Trial: 27171508
Drug: Alogliptin (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin (any treatment group)
Trial: 25511300
Drug: NaF solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaF solution at pH4.5
Trial: 25511300
Drug: NaF solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaF solution at pH7.0
Trial: 22069045
Drug: PEG‐IFNα‐2b plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFNα‐2b plus lamivudine 100 mg/d
Trial: 22069045
Drug: PEG‐IFNα‐2b 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFNα‐2b 1.5 µg/kg o. i. w.
Trial: 12196081
Drug: Fondaparinux (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux (2.5 mg, once daily, starting 6 hours after surgery)
Trial: 9706946
Drug: Cisatracurium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.25 mg/kg
Trial: 10527226
Drug: Vecuronium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.15 mg/kg
Trial: 389838
Drug: Indomethacin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (3 x 25 mg/day)
Trial: 389838
Drug: Combined indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined indomethacin + sodium-salicylate (3 x 25 mg/day and 3 x 250 mg/day)
Trial: 19830413
Drug: Pummelo juice
RxNorm normalized name: pummelo extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pummelo juice with 50 mg sildenafil
Trial: 19830413
Drug: Water with
RxNorm normalized name: sterile water with electrolytes injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water with 50 mg sildenafil
Trial: 14763193
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of quinacrine at each cornual angle (3 double insertions, a month apart)
Trial: 14763193
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of quinacrine at each cornual angle (single double insertion)
Trial: 14763193
Drug: 252 mg
RxNorm normalized name: menthol 0.0252 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 252 mg to 360 mg of quinacrine (2 insertions, a month apart, fundal placement)
Trial: 11030470
Drug: Nateglinide 120
RxNorm normalized name: nateglinide 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 120 mg 3 times daily before meals
Trial: 11030470
Drug: Nateglinide 120
RxNorm normalized name: nateglinide 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 120 mg plus metformin 500 mg, both 3 times daily
Trial: 11030470
Drug: Nateglinide 60
RxNorm normalized name: nateglinide 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 60 or 120 mg 3 times daily plus metformin 1 g twice daily
Trial: 11030470
Drug: Nateglinide 120
RxNorm normalized name: nateglinide 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 120 mg 3 times daily
Trial: 11030470
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with troglitazone 600 mg daily
Trial: 8654613
Drug: All patients
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients after chemotherapy
Trial: 1794820
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution (controls) in the anterior chamber
Trial: 6212962
Drug: Amitriptyline 75
RxNorm normalized name: amitriptyline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 75 mg + Ethanol 50 g
Trial: 6212962
Drug: Zimelidine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine 200 mg + Ethanol 50 g
Trial: 6212962
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Ethanol 50 g
Trial: 30106333
Drug: No desensitizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No desensitizer treatment
Trial: 26499112
Drug: 1.8 ml
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 ml of 0.5% hyperbaric bupivacaine at 5 °C (group I, n = 50)
Trial: 26499112
Drug: 1.8 ml
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 ml of 0.5% hyperbaric bupivacaine at 23 °C (group II, n = 50)
Trial: 12542209
Drug: Caroverine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caroverine (120 mg/day for 4 weeks)
Trial: 12542209
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (400 mg/day for 4 weeks)
Trial: 2535284
Drug: Bupivacaine/methylprednisolone solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine/methylprednisolone solution (22 ml) injected over 2 minutes in horizontal position
Trial: 2535284
Drug: Bupivacaine/methylprednisolone solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine/methylprednisolone solution (22 ml) injected over 2 minutes with 15 degrees head-up tilt
Trial: 2535284
Drug: Bupivacaine/methylprednisolone solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine/methylprednisolone solution (22 ml) injected over 2 minutes with 15 degrees head-down tilt
Trial: 31614214
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBTI) - 6 sessions delivered via telephone
Trial: 23063111
Drug: Multicomponent exercise
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent exercise training (90 min, twice a week for six months)
Trial: 15124190
Drug: Sonographic assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonographic assessment of clubfoot during treatment
Trial: 3296728
Drug: Pirmenol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirmenol (50 mg intravenous bolus followed by 2.5 mg/min infusion)
Trial: 3296728
Drug: Lidocaine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (75 mg intravenous bolus followed by 3 mg/min infusion)
Trial: 26647072
Drug: Treatment guidance
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment guidance based on continuous glucose monitoring (CGM) data
Trial: 20973155
Drug: Oxycodone (OX)
RxNorm normalized name: OX BILE
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone (OX) 20 mg/d
Trial: 20973155
Drug: Morphine (MO)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (MO) 30 mg/d
Trial: 18540331
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tramadol extended-release capsules (T-long) administered in the morning
Trial: 18540331
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tramadol extended-release capsules (T-long) administered in the evening
Trial: 18540331
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tramadol extended-release capsules (T-long) administered in the morning and evening
Trial: 15787899
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus weekly telephone contact by a diabetes nurse educator (DNE) for 6 months.
Trial: 12736400
Drug: Daily iron-folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily iron-folate supplementation
Trial: 12736400
Drug: Weekly iron-folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly iron-folate supplementation
Trial: 11014412
Drug: IY-81149 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IY-81149 10 mg
Trial: 11014412
Drug: IY-81149 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IY-81149 20 mg
Trial: 11014412
Drug: IY-81149 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IY-81149 5 mg
Trial: 8676802
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (HPD) 1.6 g/kg BW + Enalapril (ENAL) 10 mg/day
Trial: 8676802
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (LPD) 0.8 g/kg BW
Trial: 1450309
Drug: PCA device
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA device Prominject with fentanyl demand doses of 34 micrograms, lockout time of 1 min, no concurrent infusion
Trial: 1450309
Drug: PCA device
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA device ODAC with fentanyl demand doses of 34.5 micrograms, lockout time of 5 min, fixed-rate infusion of 4 micrograms/h
Trial: 1450309
Drug: PCA device
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA device Prominject with tail-dose, fixed-rate infusion of 17 mg/h for a maximum of 60 minutes following a valid demand
Trial: 1450309
Drug: PCA device
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA device ODAC with adaptive-rate infusion starting with 4 micrograms/h, adapted to individual needs
Trial: 6421429
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment with antibiotics
Trial: 3555277
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral bisacodyl
Trial: 23307845
Drug: EB/TBA (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EB/TBA (14 mg estradiol benzoate and 100 mg trenbolone acetate)
Trial: 23307845
Drug: EB (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EB (14 mg estradiol benzoate)
Trial: 23307845
Drug: TBA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBA (100 mg trenbolone acetate)
Trial: 17070196
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/d)
Trial: 17070196
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) (100 mg/d)
Trial: 12075708
Drug: Clear topical
RxNorm normalized name: Lyclear Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear topical ointment
Trial: 12075708
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ointment)
Trial: 9861383
Drug: Triclabendazole, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triclabendazole, 5 mg/kg once daily for 3 days
Trial: 9861383
Drug: Triclabendazole, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triclabendazole, 10 mg/kg twice on one day
Trial: 9861383
Drug: Triclabendazole, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triclabendazole, 10 mg/kg in a single dose
Trial: 9861383
Drug: Praziquantel, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel, 25 mg/kg thrice daily for 3 days
Trial: 9861383
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 10 mg/kg
Trial: 2167564
Drug: smallpox vaccine
RxNorm normalized name: SMALLPOX VACCINE
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: smallpox vaccine
Trial: 736080
Drug: Microdrops (0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdrops (0.005 or 0.01 ml) of a mixture of 5% phenylephrine HCl and 0.5% tropicamide HCl
Trial: 736080
Drug: Diluted solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted solutions (0.005 or 0.01 ml)
Trial: 23208965
Drug: Hypocaloric commercial
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric commercial formula (Optisource®) - 1109.3 kcal/day, 166.4 g carbohydrates, 63 g proteins, 21.3 g lipids
Trial: 20833591
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg once daily)
Trial: 12829200
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with hydrocortisone (5 mg/d) and fludrocortisone (50 microg/d)
Trial: 1771395
Drug: Ketoprofen, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen, 200 mg/day (50 mg q.i.d.) for 7 days
Trial: 25180798
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate 20 mg
Trial: 25159886
Drug: Active treatments
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatments (Lisdexamfetamine dimesylate and Armodafinil)
Trial: 18541739
Drug: Single-tooth extraction
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-tooth extraction with amoxicillin prophylaxis
Trial: 16003653
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (10 g/d x 10 d presurgery to 5 g/d x 30 d postsurgery)
Trial: 10811324
Drug: Euglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia (blood glucose, 6 mmol/L)
Trial: 10811324
Drug: Hyperglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (blood glucose, 15 mmol/L)
Trial: 1800430
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives (OC) with levonorgestrel (LNG) and norethisterone acetate (NEA)
Trial: 1800430
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives (OC) with levonorgestrel (LNG)
Trial: 26603258
Drug: GSK2126458 (GSK458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2126458 (GSK458) at a maximum tolerated dose (MTD) of 2.5 mg once daily or twice daily dosing.
Trial: 26603258
Drug: GSK2126458 (GSK458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2126458 (GSK458) at doses ranging from 0.1 to 3 mg once or twice daily.
Trial: 26603258
Drug: GSK2126458 (GSK458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2126458 (GSK458) at a maximum tolerated dose (MTD) of 2.5 mg once daily.
Trial: 22183158
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium 50 mg kg(‐1)
Trial: 20382272
Drug: Transdermal drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal drug delivery system (TDDS) of Carvedilol (CRV)
Trial: 20382272
Drug: Transdermal drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal drug delivery system (TDDS) of Hydrochlorothiazide (HCTZ)
Trial: 20382272
Drug: Conventional immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immediate release oral tablets of Carvedilol (CRV)
Trial: 20382272
Drug: Conventional immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immediate release oral tablets of Hydrochlorothiazide (HCTZ)
Trial: 17284744
Drug: Daily supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplement containing folate (1 mg), vitamin B‐12 (500 microg), and vitamin B‐6 (10 mg)
Trial: 16084158
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg 3 times daily